Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Upgraded by Cantor Fitzgerald

Fulcrum Therapeutics (NASDAQ:FULC) was upgraded by equities research analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a report released on Thursday, Marketbeat reports. The firm presently has a $10.00 price target on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 45.35% from the company’s previous close. Cantor Fitzgerald also issued estimates for Fulcrum Therapeutics’ FY2025 earnings at ($1.21) EPS.

Separately, HC Wainwright restated a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.50.

Fulcrum Therapeutics Price Performance

Shares of FULC stock opened at $6.88 on Thursday. Fulcrum Therapeutics has a 1-year low of $2.32 and a 1-year high of $10.13. The firm has a market cap of $371.38 million, a PE ratio of -22.19 and a beta of 2.29. The company has a 50-day moving average of $3.69 and a two-hundred day moving average of $3.79.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. Sell-side analysts anticipate that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in FULC. MetLife Investment Management LLC lifted its holdings in Fulcrum Therapeutics by 145.8% during the 4th quarter. MetLife Investment Management LLC now owns 40,107 shares of the company’s stock worth $189,000 after buying an additional 23,792 shares in the last quarter. Barclays PLC increased its position in shares of Fulcrum Therapeutics by 367.1% during the third quarter. Barclays PLC now owns 124,141 shares of the company’s stock worth $443,000 after acquiring an additional 97,565 shares during the period. American Century Companies Inc. raised its stake in shares of Fulcrum Therapeutics by 5.9% in the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company’s stock valued at $567,000 after acquiring an additional 6,770 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Fulcrum Therapeutics by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company’s stock valued at $161,000 after purchasing an additional 8,761 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Fulcrum Therapeutics by 176.8% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 367,594 shares of the company’s stock valued at $1,728,000 after purchasing an additional 234,810 shares during the period. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.